Research programme: drug discovery - Dermira/Evotec SE
Latest Information Update: 28 Jun 2021
At a glance
- Originator Dermira; Evotec AG
 - Developer Dermira; Evotec SE
 - Class Skin disorder therapies
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Neurological disorders; Pruritus
 
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Neurological-disorders in Germany
 - 28 Jun 2021 No recent reports of development identified for research development in Neurological-disorders in USA
 - 28 Jun 2021 No recent reports of development identified for research development in Pruritus in Germany